Stallion India Fluorochemicals Ltd

- The company has taken Board approval to raise up to INR 500 crore but does not intend to dilute equity or fully utilize this limit immediately. - Current CapEx spends are funded in-house. - For future funding, the company is considering multiple options: debt, equity, or amortization advances from customers (OEMs willing to fund and amortize over time). - The choice of funding route will depend on what suits best for faster execution and maintaining financial stability. - Initially, the first manufacturing plant funding will likely be through equity (post-IPO), while subsequent expansions may consider debt or equity based on market conditions. - The company is open to non-traditional funding through customer advances, potentially reducing the need for debt or equity issuance.

- CapEx of approximately INR 200 crore planned for manufacturing R-32 refrigerant plant. - New manufacturing plants planned in a series, with the first plant serving as a learning experience; subsequent plants to be larger in scale. - Khalapur and Mambattu facilities expected to be operational by November 2025, contributing incrementally to revenue starting FY26. - Rajasthan manufacturing facility expected to start production by mid-2026. - Planned capacity expansions to significantly enhance turnover, aiming to add INR 135 crore in the first year and INR 270 crore in the second year from the initial manufacturing plant. - Funding will be through a combination of equity, debt, or customer advances with priority on maintaining financial stability. - Company targeting a turnover of INR 2,500 crore by 2030 through multiple phased expansions.

- Stallion India Fluorochemicals targets a significant growth trajectory aiming to reach INR 2,500 crore in turnover by 2030, implying several times growth from current levels. - Growth will be driven by a series of manufacturing plants, starting with a 5,000-ton plant expected to add around INR 135 crore turnover in the first year and INR 270 crore in the next. - Expansion plans include additional plants beyond the initial one, each larger and expected to generate higher revenues, contributing to multi-fold growth rather than just 30-35% CAGR. - Incremental revenues from the upcoming Mambattu, Khalapur, and Rajasthan plants are expected to notably increase from 2026 onwards. - The company aims to maintain consistent project execution with overlapping project timelines to ensure steady growth. - The growth strategy is planned explicitly for a 5-year horizon, focusing on tangible milestones by 2029-2030.

- Stallion India Fluorochemicals targets a significant growth trajectory with a five-year vision to reach INR 2,500 crore in turnover by 2030. - Current PAT margins hover around 9-11%; with manufacturing expansion, PAT is expected to rise to 24%. - Specialty gases (helium, semiconductor) business projected to deliver 18-20% PAT margins. - Overall blended PAT margin expected around 17-18% as manufacturing scales up. - Incremental revenues from new plants (Khalapur, Mambattu, Rajasthan) expected to contribute substantially from FY26 onwards, with full-scale operations starting post-November 2025. - Company aims for multi-fold growth by FY29, beyond the current 30-35% CAGR guidance. - Manufacturing expansion supported by phased CapEx and capital market funding, enabling accelerated growth and improved EBITDA margins possibly near 30% at scale. - Initial quarters post-commissioning may show modest revenue, but significant ramp-up anticipated in subsequent periods.

- The company currently has an order book, but immediate impact may not be visible in revenues. - Real impact from new plants and orders expected from April onwards. - HFO business is currently limited in India; demand is mostly from new projects and export-driven growth. - Orders for HFO-based transitions (e.g., Reliance's facility) are expected around April. - Specialty gases like helium are tender-based; tenders may occur around March, covering quantities for the next 9 months. - Order inflows and revenues from these new segments may not be visible immediately in Q1 but expected to reflect over the annual cycle.